Asked by: Iqbal Mohamed (Independent - Dewsbury and Batley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to expand the provision of (a) palliative and (b) end-of-life care in the community.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We want a society where every person receives high-quality, compassionate care from diagnosis through to the end of life.
Palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative and end of life care. ICBs, including the Staffordshire and Stoke-on-Trent ICB, which covers the Stafford constituency, are responsible for the commissioning of palliative and end of life care services, to meet the needs of their local populations. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
As set out in the Government’s recently published 10-Year Health Plan, we are determined to shift more care out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services, including hospices, will have a big role to play in that shift, and were highlighted in the plan as being an integral part of neighbourhood teams.
The Government and the National Health Service will closely monitor the shift towards the strategic commissioning of palliative and end of life care services to ensure that, in future, services reduce variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Officials will present further proposals to ministers over the coming months, outlining how to operationalise the required shifts in palliative care and end of life care to enable the shift from hospital to community, including as part of neighbourhood health teams.
Asked by: Iqbal Mohamed (Independent - Dewsbury and Batley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the 10-Year Plan for Health enables equitable access to (a) palliative and (b) end-of-life care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Integrated care boards (ICBs) are responsible for the commissioning of palliative and end of life care services, to meet the needs of their local populations. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
One of the three shifts that the 10-Year Health Plan will deliver is the shift of healthcare from the hospital into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift and were highlighted in the plan as being an integral part of neighbourhood teams.
I have tasked officials to look at how to improve the access, quality, and sustainability of all- age palliative and end of life care, in line with the 10-Year Health Plan.
Asked by: Iqbal Mohamed (Independent - Dewsbury and Batley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the review of the early access to medicines system will include Early Access Programmes of the type used for Givinostat; and what steps he is taking to (a) help tackle geographic variations in uptake and (b) improve equitable access to innovative treatments across the NHS.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Rare Diseases Framework sets out improving access to specialist care, treatments, and drugs as a priority, and health equity as a cross-cutting theme. The Department understands the importance of rapid patient access to new medicines for patients with Duchenne muscular dystrophy and has worked with NHS England to consider the issues raised by the Givinostat early access programme.
We are also working to review the effectiveness of access schemes for rare disease therapies. This will focus on the Early Access to Medicines Scheme, the Innovative Licensing and Access Pathway, and the Innovative Medicines Fund, but will broadly consider access to rare disease therapies.
Asked by: Iqbal Mohamed (Independent - Dewsbury and Batley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has considered providing (a) funding and (b) other support to NHS Trusts to participate in early access programmes for (i) Givinostat for Duchenne Muscular Dystrophy and (ii) other medicines.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department understands the importance of rapid patient access to new medicines for patients with Duchenne muscular dystrophy, and has worked with NHS England to consider the issues raised by the givinostat early access programme. The first National Institute for Health and Care Excellence (NICE) committee meeting for givinostat took place on 10 July 2025, with a provisional date for a decision in September. If the manufacturer, Italfarmaco, can offer a cost-effective price to enable a positive NICE recommendation, NHS England is ready to work with the company to explore immediate funding options for the treatment.
Although medicines administered via company-sponsored early access programmes (EAPs) are licensed, EAPs do not share common clinical, data, or regulatory standards, meaning each one demands a new protocol to be devised and delivered by each participating trust, and that can create significant pressures on clinical and financial resources.
It would not be appropriate for the Government or NHS England to issue any form of national direction around the participation in these early access programmes as it would both pre-empt and undermine the role of NICE, whose very purpose is to advise the National Health Service on whether or not particular treatments should be made routinely available on the NHS.
The Government does, however, support patients getting early access to new, innovative medicines through established routes such as the Early Access to Medicines Scheme.